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a  b  s  t  r  a  c  t
Metastatic carcinoma to the vulva is rare, where the incidence is believed to be between 5%
and  8%.
However, malignant tumors have been described in 3–11% of systemic scleroderma (SSc)
cases.
We  report the case of one patient, a 66-year-old postmenopausal woman, whose medical
history was marked with rheumatic vascular disease (systemic scleroderma) since 1993
without muscular, renal, cardiac lesions or HTA (arterial hypertension) and without tobacco
history.
The woman presented with a new vulvar mass of the right labia in December 2011 that
had  progressively enlarged in size.
CT scan of the abdominopelvic region demonstrated a lobular mass of the right labia with
central necrosis, 7 cm on the wide axis, and the rectum and the vaginal wall were normal.
No  inguinal or iliac lymphadenopathy was noted.
An outpatient excisional biopsy revealed a poorly differentiated malignant tumor sugges-
tive of carcinoma.
IHC: CK7+/CK20−,  estrogen receptors−, AE 1 AE 3+, vimentine+, S100−, Desmina−, CD34−,
KI  67: 20%.
The thoracic scan revealed a large mass of 4 cm × 3 cm in the right lung base with right
paratracheal lymphadenopathy 3 cm × 2 cm.A  bronchoscopy revealed discrete stenosis of the mediastinal portion of the right bronchialtree.
The  bronchial biopsy also revealed poorly differentiated lung carcinoma, non-small cell,
which was identical with the vulvar tumor.
Conclusion: The presence of the single lung lesion with only one lymphadenopathy paratra-
cheal  with pathological and immunohistochemical (IHC) proﬁle similar to the vulvar lesion,
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and a particular IHC proﬁle with CK7+ and CK20− was detected – that is more speciﬁc to
the  primitive pulmonary cancer, and the presence of only one sarcoma marker vementine+,
desmine and actine−. Also the presence of KI 67: 20%, predicted the proliferative and great
metastatic power of the lung tumor was observed.
Additionally, lung cancer was the most frequent type and may develop in scleroderma as
reported in most studies.
This allows to conclude for primitive lung carcinoma revealed with vulvar metastasis after
elimination of the possibility of vulvar sarcoma.
The patient was treated by chemotherapy (Taxol/Platin) with partial response from the lung
after 3 cycles and palliative radiotherapy in the vulva with a good response.
This  case described primary lung carcinoma associated with scleroderma, revealed by a
vulvar metastasis, which may be related to the aggressiveness of lung cancer when the lung
ﬁbrosis follow-up is not performed well to detect early the development of lung tumors in
the  patient with systemic scleroderma.
© 2013 Greater Poland Cancer Centre. Published by Elsevier Urban & Partner Sp. z o.o. All
rights reserved.





Le carcinome métastatique de la vulve est rare, son incidence est estimé entre 5% et 8%.
D’autre part les tumeurs malignes ont été décrite dans 3-11% de la sclérodermie systémique
(ScS) cas.
Nous rapportons le cas d’une patiente, 66 ans ménopausée, ses antécédents médicaux ont
été  marquée par une maladie vasculaire rhumatismale (sclérodermie systémique) depuis
1993 sans atteintes musculaires, rénales, cardiaques ou HTA (hypertension artérielle) et sans
histoiretabagique.
La  patiente a représenté une masse vulvaire de la lèvre droite de la vulve en Décembre 2011,
qui  avait progressivement augmenté de taille.
La tomodensitométrie abdomino-pelvienne a montré une masse lobulaire de la lèvre droite
avec  une nécrose centrale, 7 cm l’axe le plus large, le rectum et la paroi vaginale étaient
normale. Aucune adénopathie inguinale ou iliaque a été noté.
Une biopsie-exérèse ambulatoire a révélé une tumeur maligne peu différenciée suggérant
un  cancer.
IHC: CK7+/CK20−, récepteurs des oestrogènes−, AE 1 AE 3+, vimentine+, S100−, Desmina−,
CD34−,  KI 67: 20%.
Le scanner thoracique a révélé une grosse masse de 4 × 3 cm au niveau de la base du poumon
droit avec lymphadénopathie paratrachéaux droite de 3 × 2 cm.
Une bronchoscopie a révélé: une sténose de la partie médiastinale de l’arbre bronchique
droit. Et la biopsie bronchique a révélé un carcinome du poumon peu différencié, non à
petites cellules, ce qui était identique à la tumeur vulvaire.
Conclusion: La présence de la lésion pulmonaire unique avec un seul lymphadénopathie
paratrachéal avec à l’anatomopathologie et immunohistochimie (IHC) un proﬁl similaire à
la  lésion vulvaire, et le proﬁl IHC particulier avec CK7+ et CK20− qui sont plus spéciﬁques
au  cancer primitif pulmonaire, et la présence d’un seul marqueur de sarcome vementine+,
desmine et actine−. Aussi la présence de KI 67: 20%, qui prédit le grand pouvoir prolifératif
et  métastatique de la tumeur pulmonaire.
En  plus le cancer du poumon est le type de cancer le plus fréquent qui peut se développer
chez les patients sclérodermiques dans la plupart des études.
Ces arguments ont permis de conclure au carcinome primitif du poumon révélé par des
métastases vulvaire après élimination de la possibilité de sarcome vulvaire.
Traités par chimiothérapie (Taxol/Platin) avec une réponse partielle au niveau du poumon
après 3 cycles et radiothérapie palliative de la vulve avec une bonne réponse.
Ce  cas décrit un carcinome primitif du poumon associé à une sclérodermie systémique,
révélé par une métastase vulvaire, qui peut être lié à l’agressivité du cancer pulmonaire
lorsque le bon suivi de la ﬁbrose pulmonaire n’est pas effectué pour le dépistage précoce des
tumeurs pulmonaires développées chez des patients suivis pour sclérodermie systémique.
©  2013 Greater Poland Cancer Centre. Publicado por Elsevier Urban & Partner Sp. z o.o.
Todos los derechos reservados.
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Fig. 1 – Inﬂammatory mass from the right vulva.
Fig. 2
The patient was referred for oncological consultation, and
the new physical exam found crackles in the basal right lung.1.  Introduction
Scleroderma is a chronic, multisystem, autoimmune disease.
Previous studies have shown an increased risk of malignancy
in scleroderma; the most common cancers were lung cancer
and breast cancer.
The lung cancer present at an advanced stage where pallia-
tive measures are utilized have a high propensity for distant
metastases.
Metastatic carcinoma to the vulva is rare, the incidence is
believed to be between 5% and 8% based on two large series
from the Washington University School of Medicine. Lung can-
cer with metastasis to the vulva is very rare. One case has
been reported in the literature as the presentation of lung
carcinoma as a vulvar metastasis.
We reported one case of lung cancer developed by a non-
smoking woman  with scleroderma in whom the mean disease
duration was 18 years at the time of lung cancer diagnosis
revealed at metastatic stage. This case revealed the interest
for a good lung ﬁbrosis follow up of the patient with sclero-
derma, especially that SSc patients have risk factors for the
development of malignancy.
2.  Case  report
We  report the case of one patient, a 66-year-old post-
menopausal woman, whose medical history was marked with
rheumatic vascular disease (systemic sclerodermy) with dif-
fuse cutaneous (dcSSc) clinical subtype, overall decrease in
number of capillaries, but without muscular, renal or cardiac
lesions or HTA, and without tobacco history.
ANA (antinuclear antibodies) (+) and anti-scl70 (+), with
disease duration of 18 years. With the vitamin D deﬁciency.
The last thoracic scan in 2008 revealed a minimal bilateral
basal pulmonary and peripheral ﬁbrosis without alveolitis.
The woman presented with a new vulvar mass of the right
labia in December 2011 that had progressively enlarged in size.
The patient’s exam found a 4 cm × 4 cm,  ﬁrm, irregularly
contoured and mobile inﬂammatory mass protruding from
the right vulva just lateral to the perineal body (Figs. 1 and 2).Bimanual and rectovaginal exam did not reveal vaginal or
rectal involvement of the mass.
The remaining vulva, vagina, and vaginal cuff were with-
out other notable lesions and there was no palpable inguinal
lymphadenopathy.
CT scan of the abdominopelvic region demonstrated a lob-
ular mass of the right labia with central necrosis measuring
7 cm in the wide axis, and the rectum and the vaginal wall was
normal. The mass appeared to be contiguous with the obtu-
rator internus muscle and extended through the skin of the
perineum. No inguinal or iliac lymphadenopathy was noted.
No other lesions in the abdomen were found. Metastasis of
the vulva is shown in Figs. 3 and 4.
An outpatient excisional biopsy revealed a poorly differ-
entiated malignant tumor suggestive of IHC: CK7+/CK20−,
estrogen receptors−,  AE 1 AE 3+, vimentine+, S100−,
Desmina−, CD34−, KI 67: 20%.Fig. 3 – CT scan image for the tumor of the vulva.




Fig. 6 – Scan image of tumor in the right lung base.Fig. 4 – CT scan image for the tumor of the vulva.
The thoracic scan was performed and revealed a large mass
f 4 cm × 3 cm in the right lung base with right paratracheal
ymphadenopathy 3 cm × 2 cm (Figs. 5 and 6).A bronchoscopy revealed: discrete stenosis of the mediasti-
al portion of the right bronchial tree.
Fig. 5 – Scan image of paratracheal lymphadenopathy.And the bronchial biopsy revealed poorly differentiated
lung carcinoma, non-small cell, which was identical with the
vulvar tumor.
3.  Results
The history of scleroderma and the presence of risk factors
for the development of malignancy, especially lung cancer,
including female gender (older age at the time of diagno-
sis), and the diffuse cutaneous (dcSSc) clinical subtype, the
presence of the single lung lesion with only one paratracheal
lymphadenopathy with pathological and immunohistochem-
ical (IHC) proﬁle similar to the vulvar lesion, and the particular
IHC proﬁle with CK7+ and CK20− that are speciﬁc to the
primitive pulmonary cancer and the presence of KI 67 20%,
predicted the proliferative and great metastatic power of the
lung tumor.
Also the presence of only one sarcoma marker vementine+,
desmine and actine− was observed.
This allows to conclude for primitive lung carcinoma at
the metastatic stage IV revealed with vulvar metastasis after
elimination of the possibility of vulvar sarcoma.
The patient was treated by giving chemotherapy with par-
tial response in the lung after 3 cycles CDDP/TAXOL but
without improvement of sclerodermatous skin lesions, and
palliative radiotherapy 30gry (10 × 3) in the vulva.With good regression of tumor of the vulva (Fig. 7).
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Fig. 7 – Vulvar masse before radiotherapy. Vulvar masse
patient with scleroderma; it could be a paraneoplastic
syndrome. Therefore, the history of scleroderma, with dis-
ease duration of 18 years and the lack of improvementafter palliative radiotherapy.
4.  Discussion
In the large series from the Washington University School
of Medicine, the most common sites of primary tumors of
metastatic cancer to the vulva are the cervix, ovaries, and
endometrium.
In our case the primary tumor was rare; it was the lung,
and its histological type was carcinoma poorly differentiated
malignant tumor. This type has a high propensity for distant
metastases and it is often incurable, when metastases are
present, the same as in our case, revealed by vulvar metastasis
where palliative measures were used.
In our case the question was to determine whether the
tumor is primary: vulvar sarcoma with lung metastasis or lung
cancer with metastasis in vulva.
A biopsy of the chest lesion revealed poorly differentiated
carcinoma, with histology identical to the vulvar biopsy.
In this case, considering the immunoproﬁling played an
important role in guiding the diagnosis: staining for TTF-1
was present and the pattern of differential cytokeratins, CK7
(positive) and CK20 (negative) could be seen with poorly dif-
ferentiated primary carcinomas of the lung cancer.
However the sarcoma of the vulva was eliminated after IHC
with desmin (−), actine liss muscle (−), and only vimentine
(poorly+).CD34(−), CD45(−),  S100(−), RE(−), p63(−). KI67(+): 20%: pre-
dicted the proliferative and metastatic great power of the
tumor.iotherapy 1 8 ( 2 0 1 3 ) 182–188
The CT scan was used to help and conﬁrm our diagno-
sis. It was demonstrated a single lesion in the right lung base
with only a single right paratracheal lymphadenopathy, while
the metastatic lesions were most often by multiples dropped
ball.
4.1.  Vitamin  D  carence  and  lung  cancer
What is more,  the patient had also the vitamin D deﬁciency,
representing one of the factors promoting the development of
certain types of cancer.
Calcitriol (1,25-dihydroxyvitamin D3), the hormonally
active form of vitamin D, is involved in key regulatory pro-
cesses such as proliferation, differentiation and apoptosis in
a wide variety of cells, as it causes the suppression of inﬂam-
mation and exerts growth inhibitory effects. Mechanisms for
these actions have been proposed to be the interaction of
active vitamin D derivatives with a speciﬁc nuclear receptor
(VDR receptor) and/or with membrane targets. In vitro stud-
ies, performed with lung cancer cell lines, have shown an
inhibitive effect of vitamin D derivatives on cell-growth and
proliferation.
Furthermore, animal studies have demonstrated the capa-
bility of these compounds to suppress invasion, metastasis
and angiogenesis in vivo, suggesting that administration of
vitamin D derivatives may be used as an adjuvant therapy for
lung cancer.
The institute for cancer research of Montbello, Norway pre-
sented the work that aimed at investigating the impact of
season of diagnosis and residential region, both inﬂuencing
the vitamin D level, on the risk of death from lung cancer in
patients diagnosed in Norway.1
Data on all incident cases of lung cancer between 1964 and
2000 were collected. Risk estimates were calculated as relative
risk (RR), with 95% conﬁdence intervals using Cox regression
model. The seasonal variation of 25-hydroxyvitamin D was
proposed, as a high level of sun-induced 25-hydroxyvitamin
D can be a prognostic advantage for certain groups of lung
cancer patients, notably for young men.
Assessments were made from routine measurements of
samples performed at the Hormone Laboratory of Aker Uni-
versity Hospital.15,16
These results indicate that season of diagnosis is of pro-
gnostic value for lung cancer patients, with a ≈15% lower case
fatality for young male patients diagnosed during autumn
versus winter (RR = 0.85; 95% CI, −0.73 to 0.99; P = 0.04). Resid-
ing in a high UV region resulted in a further lowering of the
death risk than residing in a low UV region.
4.2.  Systemic  scleroderma  and  lung  cancer
The strongest argument, however, was the history of theof scleroderma lesion after lung chemotherapy suggested
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So, this lung cancer was probably a secondary tumor to
atient’s systemic scleroderma.
Indeed, among solid malignancies, lung cancer was the
ost frequent type of cancer in most studies, followed by
reast, esophageal cancer and lymphomas.
In scleroderma, cancer may develop in organs affected by
brosis, such as the lungs, esophagus or skin.
The higher incidence of lung cancer has been associated
ith pulmonary ﬁbrosis.
Mechanisms for these actions have been proposed. If
ossible, a facilitator role of pulmonary ﬁbrosis for cancer
evelopment. Chronic inﬂammatory processes inducing cell
amage (cell atypia, metaplasia, dysplasia) via genetic abnor-
alities (P53 mutation, microsatellite unstable, heterozygous
oss) and increased synthesis of growth factors and cytokines
brosing (TGF–PDGF).
In the patients with scleroderma of the diffuse cuta-
eous (dcSSc) subtype, the same as in our case, the antibody:
nti-topo-isomerase 1 distorted the function of this nuclear
nzyme involved in genome repair thereby facilitating onco-
enesis.
The aggressivity due to the high risk of apoptosis defect,
enomic instability and surexpression of selectin, facilitates
umoral cells migration and metastatic dissemination.
The ﬁrst example was reported by Zatuchni et al. in 1953.4
is studies assessed and calculated the relative risk of cancer
n patients followed for scleroderma at 1.5–2.1 (all back-
rounds, all types and although in the absence of smoking)
nd demonstrated that the disease duration for SSc was 5–13
ears at the time of cancer diagnosis with 22–39% of bron-
hogenic cancer.
It has been suggested that the risk of malignancy increases
ith age at the time of SSc diagnosis.
In the literature we found a large cohort of stud-
es assessing malignancies that developed in scleroderma
atients. Roumm and Medsger5 reported 14 tumor cases in
 cohort of 262 American SSc patients (5%).
Abu-Shakra et al.6 reported a 7.3% prevalence of malignan-
ies among 248 SSc patients. Lung cancer and breast cancer
ere the most common types.
Chatterjee et al.7 reported 45 cases of malignancy in a
ohort of 538 SSc patients (8.4%). Lung cancer was the most
revalent (10 cases).
According to a recent meta-analysis, the prevalence of
alignancies in SSc is between 3.6% and 10.7%.
In a majority of the cohorts, lung cancer was associated
ith both smoking and pulmonary ﬁbrosis and was the most
revalent malignancy in systemic scleroderma.
Risk factors for the development of malignancy in SSc
atients, especially lung cancer, may include:
female gender
older age at the time of diagnosis
and the diffuse cutaneous (dcSSc) clinical subtype.These factors were all present in our patient strengthening
he diagnosis of primary pulmonary.therapy 1 8 ( 2 0 1 3 ) 182–188 187
4.3.  E-cadherin–catenin  adhesion  complex  in  lung
cancer
E-cadherin, is a transmembrane glycoprotein that mediates
calcium-dependent intercellular adhesion and is speciﬁcally
involved in epithelial cell-to-cell adhesion molecule.8,9 It plays
a key role in the maintenance of tissue integrity. The function
of this molecule is partly mediated by alpha-/beta-/gamma-
catenin. Loss or dysfunction of E-cadherin is associated with
an invasive phenotype, a more  advanced tumor stage,10 and
has a role as a tumor suppressor gene.6
In the Feinberg School of Medicine, Northwestern Univer-
sity, Chicago, USA, Lam et al. reported that pulmonary ﬁbrosis
is a disease that results in the loss of normal lung architec-
ture, but the signaling events that drive tissue destruction
are incompletely understood. Wnt/beta-catenin signaling is
important in normal lung development, but whether abnor-
mal  signaling occurs in lung ﬁbrosis due to systemic sclerosis
and the consequences of beta-catenin signaling toward the
ﬁbrogenic phenotype remain poorly deﬁned. We can show
nuclear beta-catenin accumulation in ﬁbroblastic foci from
lungs of patients with systemic sclerosis-associated with
advanced pulmonary ﬁbrosis.
In our case, pulmonary ﬁbrosis secondary to scleroderma
with reduced beta-catenin and E-cadherin expression is impli-
cated in the progression and development of her lung cancer.11
In fact, Kase et al. analyzed the expression of E-cadherin
and beta-catenin in human lung cancer to determine the rela-
tionship with clinicopathological factors and prognosis.
E-cadherin and beta-catenin expressions were evaluated in
331 lung cancer tissues in an immunohistochemical analysis.
Reduced E-cadherin expression was evident in 138 (42%),
and reduced beta-catenin expression was noted in 122 (37%)
patients. Reduced E-cadherin expression signiﬁcantly corre-
lated with lymph nodes metastasis (P = 0.0199). E-cadherin
expression signiﬁcantly correlated with an increasing his-
tological differentiation (P = 0.0403). Although reduced E-
cadherin did not correlate with the prognosis (P = 0.0652),
reduced beta-catenin expression did signiﬁcantly correlate
with a poor prognosis (P = 0.0001). When both were reduced,
prognosis was signiﬁcantly unfavorable compared with either
the reduced expression (P = 0.0493) or preserved expres-
sion (P = 0.0003). Multivariate analysis showed a signiﬁcantly
lower survival rate for patients with reduced beta-catenin
(P < 0.0001).
Inactivation of the E-cadherin–catenin adhesion complex,
induced by genetic and epigenetic events, plays a signiﬁcant
role in multistage carcinogenesis, and seems to be associated
with dedifferentiation, local invasion, regional metastasis,
and reduced survival in lung cancer.12
They interpreted these data to mean that dysfunction of
the cell–cell adhesion molecule has a role in the progression of
lung cancer and that analysis of E-cadherin and beta-catenin
expression can provide clinically important evidence on which
to base treatment.13
Also, scleroderma is an autoimmune disease with a char-
acteristic vascular pathology, this vasculopathy was that
scleroderma has true capillary rarefaction, the same as in our
case, along with the loss of capillaries there was a dramatic
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molecules deﬁning this phenotype are: vascular endothelial
cadherin, a supposedly universal endothelial marker required
for tube formation (lost in the scleroderma tissue) and a
signaling molecule whose expression coincides with the end
of branching morphogenesis during development and tumor
angiogenesis.14
Immunosuppressive agents confer higher risk to develop
malignancies in SSc (systemic scleroderma)21.
In addition to the underlying disease, as described later,
some immunosuppressive and antirheumatic agents, such as
cyclophosphamide (CPH), azathioprine (AZA) or tumor necro-
sis factor  (TNF-)  inhibitors may further increase the risk of
malignancies in various rheumatic diseases.15–18
Tumorigenicity of CPH has been correlated with duration of
treatment, cumulative dose and concomitant smoking.17,19,20
Isik et al.20 have recently reported 8 cases of malignancies
in CPH treated SSc patients.
There have been much controversy regarding these
immunosuppressants, as these agents, despite their possible
carcinogenicity.
In clinical practice, CPH is usually administered for the
treatment of severe manifestations of SSc including alveoli-
tis, pulmonary ﬁbrosis, and extended skin involvement. Thus,
the expected beneﬁt may override the direct carcinogenic risk
conferred by CPH.15
In our case, patient does not have alveolitis and had local-
ized lung ﬁbrosis, so she did not receive immunosuppressants.
5.  Conclusion
Increased risk of malignancies has been associated with SSc;
the organs affected by extensive ﬁbrosis include the lungs and
esophagus and may be prone to cancer development. Cancer
risk has been associated in most cases with dcSSc and older
age, and diffuse cutaneous (dcSSc) clinical subtype like our
case with metastasis in the vulva.
Therefore, performing a close follow-up in dedicated cen-
ters is essential in order to detect the development of tumors
early.
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